Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Microsoft — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.59B), while Microsoft trades at $527.74 (market cap $3.88T). The key difference: Microsoft is far larger — about 845.3× Definium Therapeutics Inc. Common Shares's market cap, and Microsoft pays a 0.75% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Microsoft for 142 Days on average.
| DFTX | MSFT | |
|---|---|---|
Market Cap | $4.59B | $3.88T |
Volume | 2,103,937 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $48.45 | $542.07 |
52-Week Low | $10.68 | $352.83 |
Typical Hold Time | 0 Days | 142 Days |
Enterprise Value | $3.55B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Microsoft (MSFT) trades at $529.76, up 0.09% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue and net income have shown robust growth, reaching $281.72B and $101.83B in 2025, respectively. Analyst consensus is overwhelmingly positive, with 82% buy ratings and a $571.76 price target, indicating potential upside from current levels.
The outlook for MSFT remains favorable due to its leadership in AI and cloud computing, though risks include heightened capital expenditure concerns and competitive pressures. The stock's valuation multiples, such as a P/E of 29.51, reflect premium pricing but are supported by high profitability margins and growth prospects. Investors should weigh the strong institutional support against macroeconomic and sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
